Quest Diagnostics Inc: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Jul 22, 2022 and accepted by EDGAR at Jul 22, 2022, 16:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $2.45bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $5.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $1.61bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $3.26bn | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $422.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $847.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | $388.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | $901.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $38.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $75.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $77.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $187.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | $234.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | $589.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | $1.96 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | $4.88 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | $2.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | $4.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 119,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 120,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | $882.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $139.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2022-01-01 to 2022-06-30 | $152.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $573.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $790.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $2.43bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $13.31bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $1.58bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2022-06-30 | $2.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-06-30 | $6.41bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001022079-22-000123. Last ingested by Listed: Nov 13, 2026, 17:16 ET. Listed shows no prices and gives no investment advice.